Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System

NCT: NCT05754281 · ACTIVE_NOT_RECRUITING

NCT IDNCT05754281
StatusACTIVE_NOT_RECRUITING
Start Date2023-02-03
Completion2027-12-31
SponsorJoslin Diabetes Center (OTHER)
First posted
Last updated

Brief Summary

The purpose of this study is to evaluate the accuracy of the Cambridge Medical Technologies, LLC second generation (2nd Gen) LabPatch glucose sensing system compared to a laboratory glucose analyzer (YSI 2300 STAT Plus) and 2 commercial glucometers, OneTouch Verio and Freestyle Lite. The primary endpoint of this study is the mean absolute relative difference (MARD) for 2nd Gen LabPatch system compared to each of the above mentioned glucose references over a 6 hour outpatient visit.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑